Clinical Trials
6
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
1 (16.7%)Phase 3
1 (16.7%)Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
Phase 3
Completed
- Conditions
- Chronic Myeloproliferative DisordersInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Aronex Pharmaceuticals
- Registration Number
- NCT00002742
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States
🇺🇸Holt-Krock Clinic, Fort Smith, Arkansas, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
Phase 1
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00081549
Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Phase 1
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00081536
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Phase 1
- Conditions
- Esophageal NeoplasmsHepatocellular CarcinomaColorectal NeoplasmsOvarian NeoplasmsPancreatic NeoplasmsNeoplasms
- First Posted Date
- 2003-04-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00057395
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Phase 2
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Aronex Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00043199
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University Medical Center, Tucson, Arizona, United States
- Prev
- 1
- 2
- Next
News
No news found